Episode
GLP-1 Weight Loss Drugs: The science vs. the marketing with Dr. Rebecka Peebles and Nathalia Trees, RD
- Podcast
- Feisty Women's Performance
- Published
- May 25, 2026
- Duration seconds
- 3864
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/feisty-women-s-performance-3663324/episodes/glp-1-weight-loss-drugs-the-science-vs-the-marketing-with-dr-rebecka-peebles-and-nathalia-trees-rd/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/feisty-women-s-performance-3663324/glp-1-weight-loss-drugs-the-science-vs-the-marketing-with-dr-rebecka-peebles-and-nathalia-trees-rd.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr. Rebecka Peebles and registered dietitian Nathalia Trees dive into the booming world GLP-1 medications and the complex intersection of weight loss, body size, eating disorders, and marketing. They unpack the rapid rise of these weight loss drugs, the scientific and ethical dilemmas for clinicians, and practical strategies for navigating weight loss treatments. Whether you're on GLP-1s right now or considering the pros and cons of the medications, this episode will give you a clearer understanding of the risks, benefits, and long‑term considerations of these drugs. Key Takeaways Prescriptions for GLP‑1 drugs have surged since 2023, especially for adolescents, but long‑term safety data at high doses remains limited. Clinicians have to weigh metabolic benefits for diabetes against potential harm for patients with eating‑disorder histories. Transparent communication about side‑effects—GI issues, rare ocular events, and possible mood changes—is critical. Sustainable weight management, including the popular "microdosing" of GLP-1s, requires a holistic approach. Dr. Rebecka Peebles – VP of Adolescent Medicine at Monte Nido, obesity‑medicine certified, expert in GLP‑1 therapy and its application to youth. Nathalia Trees – Registered dietitian at Monte Nido, specialist in eating‑disorder treatment, weight‑inclusive care, and nutrition‑focused performance coaching. Links & Resources Guest email contacts: [email protected] | [email protected] FDA’s warning letter to Novo Nordisk Journal of Fat Studies article exposing GLP‑1 trial data gaps If you found this conversation insightful, hit Subscribe so you never miss an episode, leave a 5‑star review to help other professionals discover the show, and join the discussion on social media with Feisty Women’s Perofrmance.…